TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31940324

Group type: EXPERIMENTAL
Intervention: Anti-viral treatment
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 182
Study: 29649833

Group type: EXPERIMENTAL
Intervention: Suctioning MPCNL
Number of subjects: 912

Group type: COMPARATOR
Intervention: Standard PCNL
Number of subjects: 912

Group type: COMPARATOR
Intervention: Traditional MPCNL
Number of subjects: 912
Study: 26766184

Group type: EXPERIMENTAL
Intervention: Low intensity trail
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moderate intensity trail
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High intensity trail
Number of subjects: 10
Study: 25543415

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pseudo‐EA
Number of subjects: 70
Study: 22881991

Group type: EXPERIMENTAL
Intervention: Transporters DVD (emotion recognition skills training)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Thomas the Tank Engine DVD (control)
Number of subjects: 55
Study: 20391505

Group type: EXPERIMENTAL
Intervention: Experimental knee pain (hypertonic saline injections 0.75 ml)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Isotonic saline injections
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 34
Study: 18774702

Group type: EXPERIMENTAL
Intervention: Outpatient initiation of home mechanical ventilation (HMV)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Inpatient initiation of home mechanical ventilation (HMV)
Number of subjects: 28
Study: 16230876

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 2102

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 2102
Study: 12574429

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Elderly matched controls
Number of subjects: 26
Study: 10601914

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (1 mg micronized 17beta‐estradiol daily sequentially combined with 5 or 10 mg dydrogesterone for 14 days of each 28‐day cycle during 12 months and 2 mg 17beta‐estradiol combined with 10 mg dydrogesterone thereafter for a period of 3 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 7652679

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trial (RCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient Preference
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncommon Condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lack of Community Equipoise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methodologic Issues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical Preference
Number of subjects: 0
Study: 2245833

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) and intrauterine insemination (IUI)
Number of subjects: 67
Study: 7449382

Group type: EXPERIMENTAL
Intervention: TGLVP (0.5 mg and 1 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: LVP (0.1, 0.2, and 0.4 IU)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no drug injection)
Number of subjects: 28
Study: 6466531

Group type: EXPERIMENTAL
Intervention: Suxamethonium 10 mg pretreatment followed by 1 mg/kg suxamethonium
Number of subjects: 50

Group type: COMPARATOR
Intervention: No pretreatment with suxamethonium
Number of subjects: 50
Study: 31714912

Group type: EXPERIMENTAL
Intervention: Testosterone (Tostran 2% gel)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 29183257

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.2 g.kg-1 BM)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g.kg-1 BM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (0.07 g.kg-1 BM sodium chloride)
Number of subjects: 11
Study: 26099617

Group type: EXPERIMENTAL
Intervention: 10 cm H2O PEEP group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: FORESIGHT rSO2 values in PEEP group
Number of subjects: 44

Group type: COMPARATOR
Intervention: ZEEP group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 24858202

Group type: EXPERIMENTAL
Intervention: Early PPROM (<25.0 weeks)
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Later PPROM (≥25.0 weeks)
Number of subjects: 1531
Study: 22378800

Group type: EXPERIMENTAL
Intervention: Probiotic preparation, specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20570138

Group type: EXPERIMENTAL
Intervention: Regular touch‐screen completion of HRQOL with feedback to physicians
Number of subjects: 286

Group type: COMPARATOR
Intervention: Completion of HRQOL without feedback
Number of subjects: 286

Group type: COMPARATOR
Intervention: No HRQOL assessment
Number of subjects: 286
Study: 17584828

Group type: EXPERIMENTAL
Intervention: Mifepristone (RU486), single dose administered during the mid-secretory phase.
Number of subjects: 0
Study: 16225604

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 13

Group type: COMPARATOR
Intervention: Untreated plaques
Number of subjects: 13
Study: 12386905

Group type: EXPERIMENTAL
Intervention: Full of Ourselves: Advancing Girl Power, Health, and Leadership
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study: 10449105

Group type: EXPERIMENTAL
Intervention: anti-alpha4 integrin antibody (natalizumab; Antegren)
Number of subjects: 72

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study: 7840362

Group type: EXPERIMENTAL
Intervention: 4 mg/day of oral dexamethasone for 4 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 2404448

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerosis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerosis with surgical rescue
Number of subjects: 72

Group type: COMPARATOR
Intervention: Distal splenorenal shunt
Number of subjects: 72

Group type: COMPARATOR
Intervention: Endoscopic variceal sclerosis or distal splenorenal shunt
Number of subjects: 72
Study: 525066

Group type: EXPERIMENTAL
Intervention: 30 mg piroxicam daily for two weeks (7 patients)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 50 mg indomethacin tid for two weeks (9 patients)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Overall assessments by patients and physicians
Number of subjects: 17

Group type: COMPARATOR
Intervention: Side effects due to trial treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Laboratory test results
Number of subjects: 17
Study: 29737446

Group type: EXPERIMENTAL
Intervention: 10-session educational intervention
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control
Number of subjects: 254
Study: 27809407

Group type: EXPERIMENTAL
Intervention: The Transporters (TT) animated series
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control series
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Parental support (with)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Parental support (without)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Typically developing children (no intervention)
Number of subjects: 77
Study: 25601604

Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg encapsulated, taken 2 hours prior to intercourse for 3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24503140

Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg) plus Eicosapentaenoic acid (EPA) (1800 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pitavastatin (4 mg)
Number of subjects: 0
Study: 23692790

Group type: EXPERIMENTAL
Intervention: Medijet (MJ) system
Number of subjects: 161

Group type: COMPARATOR
Intervention: Bubble CPAP (B-CPAP)
Number of subjects: 161
Study: 19744033

Group type: EXPERIMENTAL
Intervention: icaridine 20%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: para‐menthane‐diol (PMD) 20%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: para‐menthane‐diol (PMD) 50%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DEET 50%
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 17478464

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily (o.d.)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Indomethacin 50 mg three times daily (t.i.d.)
Number of subjects: 235
Study: 15361110

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 115
Study: 11071682

Group type: EXPERIMENTAL
Intervention: Transurethral vaporization of the prostate (TUVP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 30
Study: 8638525

Group type: EXPERIMENTAL
Intervention: Organic nitrates (nitroglycerin, isosorbide dinitrate, isosorbide‐5‐mononitrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent administration of organic nitrates
Number of subjects: 0
Study: 8233745

Group type: EXPERIMENTAL
Intervention: DTP-HbOC combined vaccine (0.5 mL injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Separate administration of DTP and HbOC (0.5 mL each in separate legs)
Number of subjects: 0
Study: 2992116

Group type: EXPERIMENTAL
Intervention: Suloctidil (200 mg t.i.d.)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 29300218

Group type: EXPERIMENTAL
Intervention: Home-based HIV counseling and testing (HCT)
Number of subjects: 28
Study: 29231546

Group type: EXPERIMENTAL
Intervention: Combined therapy group with acupuncture and huazhuo jiedu jiangni decoction
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medication group with omeprazole (20 mg, twice a day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chinese herbal medicine group (decoction only)
Number of subjects: 90
Study: 26243048

Group type: EXPERIMENTAL
Intervention: Targeted percutaneous microwave ablation combined with mediastinal radiotherapy with or without chemotherapy (ablation group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Radiotherapy with or without chemotherapy (RT group)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) in ablation group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Overall survival (OS) in RT group
Number of subjects: 98
Study: 23390005

Group type: EXPERIMENTAL
Intervention: Coping Cat individual cognitive‐behavioral therapy (CBT)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Medication management with sertraline (SRT)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Combination of CBT and medication management
Number of subjects: 488

Group type: COMPARATOR
Intervention: Medication management with pill placebo (PBO)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: All treatment conditions (CBT, SRT, COMB, PBO)
Number of subjects: 488
Study: 21228609

Group type: EXPERIMENTAL
Intervention: Mirtazapine 30 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 50
Study: 18854204

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 analog BXL746 (acute administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic administration of BXL746
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (chronic administration)
Number of subjects: 0
Study: 17135584

Group type: EXPERIMENTAL
Intervention: Diet plus pioglitazone (45 mg daily)
Number of subjects: 55
Study: 12972896

Group type: EXPERIMENTAL
Intervention: Boussignac‐CPAP valve
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard oxygen delivery
Number of subjects: 30
Study: 10631204

Group type: EXPERIMENTAL
Intervention: Pleural fluid pH
Number of subjects: 433
Study: 8623862

Group type: EXPERIMENTAL
Intervention: Cited methodology references
Number of subjects: 206

Group type: COMPARATOR
Intervention: Lack of methodology reference
Number of subjects: 206
Study: 1539481

Group type: EXPERIMENTAL
Intervention: 0.33 mm (29-gauge) Quincke-type spinal needle
Number of subjects: 400

Group type: COMPARATOR
Intervention: 0.7 mm (22-gauge) Whitacre spinal needle
Number of subjects: 400
Study: 3884114

Group type: EXPERIMENTAL
Intervention: Plasma exchange therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham apheresis
Number of subjects: 20
Study: 31521118

Group type: EXPERIMENTAL
Intervention: Pentaerytrithyltetranitrate (PETN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29150952

Group type: EXPERIMENTAL
Intervention: CK-2127107 (CK-107)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27306932

Group type: EXPERIMENTAL
Intervention: Web-based questionnaire (Children's Depression Inventory, CDI)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Web-based questionnaire (Spence Children's Anxiety Scale, SCAS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Paper-and-pencil questionnaire (Children's Depression Inventory, CDI)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Paper-and-pencil questionnaire (Spence Children's Anxiety Scale, SCAS)
Number of subjects: 28
Study: 25233645

Group type: EXPERIMENTAL
Intervention: Catgut implantation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 59
Study: 23597156

Group type: EXPERIMENTAL
Intervention: Intensive program (13 multi-professional group sessions + medical consultations)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Traditional program (medical consultations only)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both programs
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Intensive program
Number of subjects: 180
Study: 20843951

Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 and 20 mg/d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 and 120 mg/d)
Number of subjects: 10
Study: 18841158

Group type: COMPARATOR
Intervention: Docetaxel-Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Docetaxel plus Imatinib
Number of subjects: 116
Study: 17132769

Group type: EXPERIMENTAL
Intervention: Daily sunscreen use
Number of subjects: 0

Group type: COMPARATOR
Intervention: No daily sunscreen use
Number of subjects: 0
Study: 12541166

Group type: EXPERIMENTAL
Intervention: Infliximab (Remicade)
Number of subjects: 21
Study: 10966959

Group type: EXPERIMENTAL
Intervention: Group B (patients with Graves' disease with ophthalmopathy)
Number of subjects: 111
Study: 8180301

Group type: EXPERIMENTAL
Intervention: NSAID usage
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: NSAID adverse reaction awareness
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Doctor-prescribed NSAID
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Daily NSAID usage
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Multiple NSAID usage
Number of subjects: 174
Study: 3131571

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 122

Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GST)
Number of subjects: 122
Study: 28925324

Group type: EXPERIMENTAL
Intervention: Multi-layer compression therapy (MLCT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard treatment with Cool Pack (CG)
Number of subjects: 16
Study: 27300752

Group type: EXPERIMENTAL
Intervention: Positive imagery cognitive bias modification (CBM‐I) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control imagery cognitive bias modification (CBM‐I) condition
Number of subjects: 0
Study: 27278477

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Time-matched standard care
Number of subjects: 30
Study: 23288353

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) target of 60-65 mm Hg for 30 min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) target of 80-85 mm Hg for 30 min (using norepinephrine infusion)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Overall effects during CPB
Number of subjects: 16
Study: 20709569

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard therapy (midazolam and opioids)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 19579987

Group type: EXPERIMENTAL
Intervention: Metoprolol (1 mg kg(‐1) daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17275274

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 3.2g
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 14963657

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (initial dosages of 60-100 mg for 7-14 days, followed by dose reduction over several months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous corticosteroids (initial dosages of 500-1,000 mg methylprednisolone at distinct intervals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous corticosteroids
Number of subjects: 0
Study: 11844203

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol, 50 microg 6‐hourly
Number of subjects: 435

Group type: COMPARATOR
Intervention: Dinoprostone gel, 1‐2 mg 6‐hourly
Number of subjects: 435
Study: 9563868

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 50
Study: 7625367

Group type: EXPERIMENTAL
Intervention: beta-interferon
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: menogaril
Number of subjects: 69
Study: 2239715

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 319204

Group type: EXPERIMENTAL
Intervention: 0.4 mg naloxone i.v.
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 4
Study: 30414387

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg followed by 90 mg twice daily (ONSET/OFFSET study)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily (PEGASUS-TIMI 54 substudy)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily (PEGASUS-TIMI 54 substudy)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo (ONSET/OFFSET study)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg followed by 75 mg once daily (ONSET/OFFSET study)
Number of subjects: 303
Study: 27923177

Group type: EXPERIMENTAL
Intervention: Exergame intervention using Xbox Kinect, 8 weeks, 3 times per week, 40 minutes per session.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 32
Study: 25880700

Group type: EXPERIMENTAL
Intervention: Supportive educational intervention based on Orem's self-care theory
Number of subjects: 66

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 66
Study: 23212457

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 12579

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 12579
Study: 21798455

Group type: EXPERIMENTAL
Intervention: Initial CAMTS training standards
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maintenance CAMTS training standards
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Overall intubation attempts
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Time per attempt
Number of subjects: 12
Study: 19494439

Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU per day for six months
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 16755160

Group type: EXPERIMENTAL
Intervention: Folate supplementation (5 mg oral daily or 5 mg every other day)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Untreated patients (Control group)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Patients with low homocysteine levels and treated with folate
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Patients with high homocysteine and low protein catabolic rate
Number of subjects: 114
Study: 15311666

Group type: EXPERIMENTAL
Intervention: Convex mirror
Number of subjects: 66

Group type: COMPARATOR
Intervention: Plane mirror
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both mirrors
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Taking-into-account model
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Direct perception model
Number of subjects: 66
Study: 10806471

Group type: EXPERIMENTAL
Intervention: Soft music (60-70 dB)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Medium music (70-80 dB)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Loud music (80-90 dB)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Heart rate monitoring
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Self-report data
Number of subjects: 144
Study: 9055717

Group type: EXPERIMENTAL
Intervention: Community thrombolysis (intravenous anistreplase administered by general practitioners)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Hospital thrombolysis (intravenous anistreplase administered by secondary care clinicians)
Number of subjects: 311
Study: 8128466

Group type: EXPERIMENTAL
Intervention: 400 U/kg rhEPO
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 800 U/kg rhEPO
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 100 U/kg rhEPO
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 200 U/kg rhEPO
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 43
Study: 3112263

Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29183752

Group type: EXPERIMENTAL
Intervention: Community-based exercise program (COMBEX)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Day hospital-based exercise program (DAYEX)
Number of subjects: 18
Study: 30621479

Group type: EXPERIMENTAL
Intervention: 1 L polyethylene glycol with ascorbic acid plus 2 mg prucalopride (1LP/AP)
Number of subjects: 260

Group type: COMPARATOR
Intervention: 2 L polyethylene glycol with ascorbic acid (2LP/A)
Number of subjects: 260